Investigational epigenetically targeted drugs in early phase trials for the treatment of haematological malignancies
Investigational epigenetically targeted drugs in early phase trials for the treatment of haematological malignancies
The identification of recurring alterations in components of the epigenome of leukaemia and lymphoma has driven the rapid development of highly potent epigenetically targeted therapies. This rapid development has alluded to the possibility of a personalised therapeutic approach in selected patient populations. An enhanced understanding of the biological effects of these epigenetic alterations in initiation and progression of haematological malignancies, together with a clear mechanistic insight into how the drugs reverse the phenotypes, will define their translation into routine clinical use.
bromodomain and extra-terminal, inhibitor, DOT1L inhibitor, epigenetics, enhancer of zeste homolog 2 inhibitor, isocitrate dehydrogenase inhibitor, leukaemia, lymphoma
1321-1332
Okosun, Jessica
52c3f45c-0fe1-4d87-b5b8-8a3028e217e7
Packham, Graham
fdabe56f-2c58-469c-aadf-38878f233394
Fitzgibbon, Jude
6afae538-ec1c-41a0-af2a-21b98dfbb356
October 2014
Okosun, Jessica
52c3f45c-0fe1-4d87-b5b8-8a3028e217e7
Packham, Graham
fdabe56f-2c58-469c-aadf-38878f233394
Fitzgibbon, Jude
6afae538-ec1c-41a0-af2a-21b98dfbb356
Okosun, Jessica, Packham, Graham and Fitzgibbon, Jude
(2014)
Investigational epigenetically targeted drugs in early phase trials for the treatment of haematological malignancies.
Expert Opinion on Investigational Drugs, 23 (10), .
(doi:10.1517/13543784.2014.923402).
(PMID:24855903)
Abstract
The identification of recurring alterations in components of the epigenome of leukaemia and lymphoma has driven the rapid development of highly potent epigenetically targeted therapies. This rapid development has alluded to the possibility of a personalised therapeutic approach in selected patient populations. An enhanced understanding of the biological effects of these epigenetic alterations in initiation and progression of haematological malignancies, together with a clear mechanistic insight into how the drugs reverse the phenotypes, will define their translation into routine clinical use.
This record has no associated files available for download.
More information
e-pub ahead of print date: 26 May 2014
Published date: October 2014
Keywords:
bromodomain and extra-terminal, inhibitor, DOT1L inhibitor, epigenetics, enhancer of zeste homolog 2 inhibitor, isocitrate dehydrogenase inhibitor, leukaemia, lymphoma
Organisations:
Cancer Sciences
Identifiers
Local EPrints ID: 385501
URI: http://eprints.soton.ac.uk/id/eprint/385501
ISSN: 1354-3784
PURE UUID: ad9fbc07-4d46-464e-a303-6de5c9839e63
Catalogue record
Date deposited: 20 Jan 2016 11:50
Last modified: 15 Mar 2024 03:05
Export record
Altmetrics
Contributors
Author:
Jessica Okosun
Author:
Jude Fitzgibbon
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
